This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Is Invesco S&P MidCap 400 GARP ETF (GRPM) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for GRPM
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Should Invesco S&P MidCap 400 GARP ETF (GRPM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for GRPM
Shockwave Medical (SWAV) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
Shockwave Medical (SWAV) concluded the recent trading session at $329, signifying a +0.45% move from its prior day's close.
Hologic (HOLX) Q2 Earnings Might Rise on GYN Surgical Growth
by Zacks Equity Research
Hologic's (HOLX) second-quarter fiscal 2024 performance is likely to be driven by the GYN Surgical portfolio.
Bio-Rad Laboratories (BIO) to Post Q1 Earnings: What Awaits?
by Zacks Equity Research
The ongoing weakness in the biopharma end markets and tightening of sanctions against Russia is likely to have hurt Bio-Rad's (BIO) first-quarter 2024 growth.
Is a Beat Likely for Edwards Lifesciences (EW) in Q1 Earnings?
by Zacks Equity Research
The strong adoption of transcatheter heart valves is expected to have led to Edwards Lifesciences' (EW) growth in the first quarter.
Hologic (HOLX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Strength in Molecular Diagnostics business and GYN Surgical is likely to have driven Hologic's (HOLX) fiscal second-quarter performance.
Align Technology (ALGN) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Align Technology's (ALGN) first-quarter 2024 performance is likely to reflect the strength of the Clear Aligner and Systems & Services businesses.
J&J (JNJ) Q1 Earnings Beat Estimates, Sales Miss, MedTech Soft
by Zacks Equity Research
J&J (JNJ) beats estimates for first-quarter earnings but misses the same for sales. It tightens its sales and earnings growth expectations for 2024.
What's in Store for Boston Scientific (BSX) in Q1 Earnings?
by Zacks Equity Research
Boston Scientific (BSX) is expected to have registered strong growth in the Asia Pacific, led by strength in China, Japan and Latin America.
What's in Store for Thermo Fisher (TMO) in Q1 Earnings?
by Zacks Equity Research
Strength in Analytical Instrument and Laboratory Products and Services segments are likely to have driven Thermo Fisher's (TMO) first-quarter 2024 performance.
Why Shockwave Medical (SWAV) Could Beat Earnings Estimates Again
by Zacks Equity Research
Shockwave Medical (SWAV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
What's in Store for Abbott Laboratories (ABT) in Q1 Earnings?
by Zacks Equity Research
Abbott (ABT) is likely to have progressed with its initiative to commercialize several biosimilars in emerging markets.
Pharma Stock Roundup: JNJ to Buy Shockwave Medical, Other Pipeline & Regulatory News
by Kinjel Shah
J&J (JNJ) is set to buy Shockwave Medical (SWAV). FDA approves AstraZeneca's (AZN) Enhertu for metastatic HER2-positive solid tumors.
Top 5 Non-Tech Nasdaq Winners of Q1 With More Upside Left
by Nalak Das
We have narrowed our search to five high-flying Nasdaq Composite listed non-tech stocks with more upside left. These are: CELH, SWAV, COIN, HOOD, IBKR.
Shockwave Medical's (SWAV) Reducer Receives Positive Results
by Zacks Equity Research
Shockwave Medical (SWAV) announces the 'real-world' results of the REDUCER-I study, which is intended to collect long-term outcomes on Shockwave Reducer, a novel treatment for refractory angina.
J&J's (JNJ) $13.1B Shockwave Deal to Boost MedTech Cardio
by Zacks Equity Research
J&J's (JNJ) proposed acquisition of Shockwave Medical (SWAV) is expected to strengthen its Medtech cardiovascular portfolio.
Acquisition Watch: Time to Buy Johnson & Johnson (JNJ) or ShockWave Medical's (SWAV) Stock?
by Shaun Pruitt
News of healthcare behemoth Johnson & Johnson (JNJ) acquiring medical device company ShockWave Medical (SWAV) for $13.1 billion made headlines this morning.
Encompass Health (EHC) Plans a 50-Bed Facility to Serve Texas
by Zacks Equity Research
Encompass Health (EHC) unveils plans to build an inpatient rehabilitation hospital in San Antonio to bring improved health outcomes and further fortify its presence in Texas.
Reasons to Add ShockWave Medical (SWAV) to Your Portfolio Now
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Acadia (ACHC) Starts Construction of Malden's JV Facility
by Zacks Equity Research
Acadia Healthcare (ACHC) initiates the construction work of the 144-bed Massachusetts-based joint venture hospital in a bid to address the need for efficient behavioral health services in the region.
Shockwave Medical (SWAV) Up on Potential Acquisition Rumors
by Zacks Equity Research
Shockwave Medical's (SWAV) shares gain as rumors about its potential acquisition by an industry giant get media attention.